Last reviewed · How we verify

terbutaline sulfate (Bricasol)

AstraZeneca · Phase 3 active Small molecule

Terbutaline sulfate is a beta-2 adrenergic receptor agonist that stimulates bronchial smooth muscle relaxation to improve airway patency and breathing.

Terbutaline sulfate is a beta-2 adrenergic receptor agonist that stimulates bronchial smooth muscle relaxation to improve airway patency and breathing. Used for Asthma (acute bronchospasm relief and maintenance therapy), Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction.

At a glance

Generic nameterbutaline sulfate (Bricasol)
Also known asBricasol pMDI
SponsorAstraZeneca
Drug classBeta-2 adrenergic agonist (short-acting bronchodilator)
TargetBeta-2 adrenergic receptor (ADRB2)
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Terbutaline binds to beta-2 adrenergic receptors on airway smooth muscle, activating intracellular signaling cascades that increase cAMP levels and promote smooth muscle relaxation. This bronchodilation effect rapidly opens constricted airways, improving airflow and reducing respiratory symptoms in obstructive airway diseases. The drug is selective for beta-2 receptors, minimizing systemic cardiovascular effects compared to non-selective beta agonists.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: